Dr. Martin Gleave

Dr. Martin Gleave

B.Sc. Physical Education, University of British Columbia
Doctor of Medicine, University of British Columbia
Fellow of the Royal College of Surgeons of Canada
Fellow, American College of Surgeons
Order of Canada

Team: 
Board of Directors
Clinical and Research Scientists
Executive Team
Positions: 

Executive Director, Vancouver Prostate Centre
Chief Executive Officer, PC-TRiADD
Distinguished Professor and Head, Department of Urologic Sciences, UBC
BC Leadership Chair in Prostate Cancer Research

 

Dr. Gleave (CM, MD, FRCSC, FACS) is a clinician-scientist and urologic surgeon. His major research focus involves the study of cellular and molecular mechanisms mediating progression of prostate cancer to its lethal stage of androgen independence, and use of this information to develop integrated multimodality therapies that specifically target these mechanisms. Dr Gleave established a role for clusterin as a cancer-related cell survival protein involved in treatment resistance and developed an inhibitor, designated OGX-011, which improved efficacy of hormone- and chemo-therapies in prostate and other cancer models. He is the scientific founder of OncoGenex Pharmaceuticals Inc. and a Member of the Order of Canada.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

PCF BC

Ride to Live 2018 and 50-50 Draw: May 27

The West Coast Motorcycle Ride to Live, raising funds for Prostate Cancer Foundation BC, takes place on Sunday May 27, 2018 in Vancouver, Victoria & the Fraser Valley. Follow the links to join a ride or donate to a rider; or to buy a ticket for a 50/50 draw (BC residents only).

Employment

Work at the Vancouver Prostate Centre

Thursday, January 18, 2018

Discovery of a promising new medication to block "master key" of cancer growth

Dr. Chris Ong
Tuesday, February 20, 2018

Drs. Wyatt and Chi: ctDNA predicts resistance to AR-targeted therapy

VCHRI News article on study of ctDNA predicting resistance to AR-targeted therapy
DNA

Make A Difference

Help the Vancouver Prostate Centre fund research to find better treatments and a cure.